Discounted Cash Flow
Silence Therapeutics Plc. ADR
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2019 | $244.0k | $-22.9m | $1.7m | -9373.0% | — |
| 2020 | $5.5m (2145.5%) | $-36.0m (-57.6%) | $-11.3m (-757.0%) | -657.8% (93.0%) | — |
| 2021 | $12.4m (126.6%) | $-45.9m (-27.2%) | $5.5m (148.7%) | -369.4% (43.8%) | — |
| 2022 | $17.5m (41.0%) | $-47.4m (-3.3%) | $-45.6m (-929.8%) | -270.7% (26.7%) | — |
| 2023 | $25.4m (45.0%) | $-50.3m (-6.2%) | $-39.4m (13.6%) | -198.3% (26.7%) | — |
| 2024 | $43.3m (70.5%) | $-45.3m (9.9%) | $-67.9m (-72.2%) | -104.7% (47.2%) | $-0.33 |
| 2025 | $559.0k (-98.7%) | $-88.6m (-95.6%) | $-62.3m (8.1%) | -15851.9% (-15034.3%) | $-0.63 (-90.9%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.